Study guide
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy
Key Takeaways Explain This Topic AI
Miscarriage classification is determined by cervical os status, symptoms, and transvaginal ultrasound (TVUS) findings: threatened (closed os, viable intrauterine pregnancy), inevitable (open os, painful bleeding, non-preventable), incomplete (open os, retained products of conception), complete (closed os, empty uterine cavity), and missed/silent (closed os, non-viable sac or fetal demise).
NICE NG126 non-viability thresholds are a mean sac diameter ≥ 25 mm with no fetal pole or a crown-rump length ≥ 7 mm with no heartbeat, confirmed by a second opinion and/or a repeat scan at least 7 days later; smaller inconclusive findings always need a rescan.
First-line management of miscarriage is expectant (7–14 days), then medical (mifepristone 200 mg then misoprostol 800 micrograms 48 hours later; misoprostol 600 micrograms alone if incomplete) or surgical; NICE gives anti-D 250 IU only to Rh-negative women having surgical management.
Tubal ectopic pregnancy presents with amenorrhoea, unilateral iliac fossa pain, dark brown bleeding, and suboptimal hCG rises; NICE NG126 offers expectant management (hCG 1,000 IU/L or less, mass < 35 mm), methotrexate (hCG < 1,500 IU/L), or laparoscopic salpingectomy (pain, heartbeat, hCG ≥ 5,000).
Hyperemesis gravidarum requires rehydration with 0.9% normal saline and potassium replacement; intravenous thiamine (Pabrinex) must strictly precede any dextrose-containing infusions to prevent acute Wernicke's encephalopathy.
Last updated: October 2026
Early Pregnancy: Miscarriage & Ectopic Pregnancy
Early pregnancy complications represent one of the most common acute presentations in acute gynaecology and primary care. Rapid clinical evaluation in an Early Pregnancy Assessment Unit (EPAU) is critical to differentiate between benign physiological bleeding, spontaneous miscarriage, and life-threatening ectopic pregnancy.
Classification & Clinical Features of Miscarriage
Miscarriage is defined as the spontaneous loss of a pregnancy before 24 completed weeks of gestation. Clinical classification depends on cervical os patency, presence of bleeding, abdominal cramping, and transvaginal ultrasound (TVUS) findings.
Miscarriage Subtype Cervical Os Status Vaginal Bleeding & Pain Transvaginal Ultrasound (TVUS) Findings Clinical Management
Threatened Miscarriage Closed Light vaginal bleeding; mild or absent suprapubic cramps Viable intrauterine pregnancy with demonstrable fetal cardiac activity Conservative / expectant management; reassurance; repeat scan if bleeding escalates. NICE NG126 (2021): offer vaginal micronised progesterone 400 mg twice daily (until 16 weeks) if there has been a previous miscarriage
Inevitable Miscarriage Open Moderate-to-heavy vaginal bleeding; progressive painful cramping Intrauterine gestational sac present, often low-lying; progression to miscarriage is unavoidable Expectant, medical, or surgical management depending on bleeding severity and patient choice
Incomplete Miscarriage Open Heavy vaginal bleeding; severe cramping pain; passage of tissue Retained products of conception (RPOC) within uterine cavity; thickened, irregular endometrium Medical management (misoprostol) or surgical evacuation (MVA/ERPC) if bleeding is heavy or infected
Complete Miscarriage Closed Bleeding and pain have largely resolved; prior passage of tissue Empty uterine cavity with endometrial thickness typically < 15 mm; no retained tissue Reassurance; home urine pregnancy test at 3 weeks to ensure complete resolution
Missed (Silent) Miscarriage Closed Minimal dark brown spotting or asymptomatic; regression of pregnancy symptoms Gestational sac containing dead embryo or anembryonic sac with no fetal heart activity Expectant (7–14 days), medical (mifepristone + misoprostol), or surgical management
Septic Miscarriage Open or Closed Malodorous purulent discharge, pelvic pain, pyrexia, uterine tenderness Retained infected products of conception Urgent hospital admission, IV broad-spectrum antibiotics, and prompt surgical uterine evacuation
Diagnostic Ultrasound Thresholds for Non-Viability (NICE NG126)
When assessing early pregnancy viability on TVUS, strict empirical thresholds prevent accidental termination of viable pregnancies:
Crown-Rump Length (CRL) Threshold: A fetal pole with a CRL ≥ 7 mm and no visible fetal heartbeat indicates miscarriage, but NICE NG126 requires a second opinion and/or a second scan at least 7 days later before the diagnosis is made.
Mean Sac Diameter (MSD) Threshold: A gestational sac with a mean sac diameter ≥ 25 mm and no visible fetal pole indicates an anembryonic pregnancy; again, seek a second opinion and/or rescan at least 7 days later before confirming.
Inconclusive Findings: If the CRL is < 7 mm without cardiac activity, or the MSD is < 25 mm without a fetal pole, the pregnancy is of uncertain viability. Repeat the transvaginal scan at least 7 days later before any diagnosis of non-viability.
Stepped Management of Spontaneous Miscarriage
Once non-viability is confirmed, management options include expectant, medical, or surgical interventions:
1. Expectant Management
First-line approach for women with confirmed miscarriage who are clinically stable, have minimal pain, and display no signs of infection or heavy haemorrhage.
The patient is observed for 7 to 14 days to allow spontaneous expulsion of retained tissue.
If bleeding and pain resolve, the patient takes a home urine pregnancy test at 3 weeks. If symptoms persist or worsen after 14 days, medical or surgical intervention is offered.
2. Medical Management
Indicated if expectant management fails, is unacceptable to the patient, or if retained products are present without severe instability.
NICE Regimen (missed miscarriage): A single oral dose of mifepristone 200 mg (a progesterone receptor antagonist that sensitises the myometrium), followed 48 hours later by misoprostol 800 micrograms (a synthetic prostaglandin E1 analogue given vaginally, orally or sublingually) to stimulate uterine contractions and cervical ripening.
Incomplete miscarriage: misoprostol 600 micrograms alone (vaginal, oral or sublingual); mifepristone is not needed.
Adequate oral analgesia (codeine, paracetamol, or NSAIDs) and antiemetics should be provided.
A urine pregnancy test is performed 3 weeks later. Persistent positive tests or unresolved symptoms require hospital follow-up to exclude gestational trophoblastic disease or retained products.
3. Surgical Management
Indications: Haemodynamic instability, severe intractable bleeding, clinical evidence of infection (septic miscarriage), or patient preference.
Modality:
Manual Vacuum Aspiration (MVA): Outpatient procedure performed under local anaesthetic and paracervical block; suitable for pregnancies up to 10–12 weeks.
Surgical Evacuation (ERPC / SMM): In theatre under general anaesthesia using suction curettage.
Anti-D Rhesus Prophylaxis
NICE NG126 (2023 update): offer anti-D immunoglobulin 250 IU within 72 hours to all rhesus D-negative women who have a surgical procedure to manage a miscarriage or an ectopic pregnancy.
Do not offer anti-D to women who have solely medical management of a miscarriage or ectopic pregnancy, a threatened miscarriage , a complete miscarriage , or a pregnancy of unknown location . Do not use a Kleihauer test to quantify feto-maternal haemorrhage in early pregnancy.
Some local haematology policies (based on British Society for Haematology guidance) still give anti-D for bleeding after 12 weeks; in an exam, follow NICE unless the question states otherwise.
Ectopic Pregnancy
Ectopic pregnancy occurs when a blastocyst implants outside the normal uterine endometrial cavity. Over 95% occur in the fallopian tube , with the ampulla being the most frequent site (~70%), followed by the isthmus (~12%), fimbria (~11%), and interstitial/cornual segment (~2%).
Clinical Presentation
Classic Triad: Amenorrhoea (typically 6–8 weeks), unilateral iliac fossa / lower abdominal pain, and abnormal dark brown vaginal spotting ("prune juice bleeding").
Signs of Tubal Rupture & Haemoperitoneum:
Sudden-onset severe sharp pelvic pain progressing to generalized peritonism.
Shoulder tip pain: Referred pain from diaphragmatic irritation by free blood in the peritoneal cavity (innervated by the phrenic nerve, C3–C5).
Tenesmus or rectal pressure due to blood pooling in the rectouterine pouch (pouch of Douglas).
Haemodynamic collapse, pallor, syncope, tachycardia, and hypotension.
Diagnostic Evaluation
Transvaginal Ultrasound (TVUS): Demonstrates an empty uterine cavity with thickened endometrium (decidual reaction / pseudo-gestational sac), an adnexal mass separate from the ovary (tubal ring or "doughnut sign"), and free fluid in the pelvis or pouch of Douglas.
Serum Beta-hCG Dynamics:
In a normal viable intrauterine pregnancy, serum beta-hCG concentrations approximately double (increase by ≥ 63%) every 48 hours .
In ectopic pregnancy, serum beta-hCG characteristically displays a suboptimal rise (< 63% rise over 48 hours) or a plateau.
Discriminatory Zone: The serum hCG level (typically 1000–1500 IU/L) above which a viable intrauterine sac must be visualized on TVUS. An empty uterus with hCG above the discriminatory zone strongly suggests ectopic pregnancy.
Treatment Modalities for Tubal Ectopic Pregnancy
Management Option Strict Eligibility Criteria Protocol & Clinical Considerations
Expectant Management Clinically stable and pain-free; tubal ectopic < 35 mm with no visible heartbeat; serum hCG 1,000 IU/L or less (consider if 1,000–1,500 IU/L); able to return for follow-up Serum hCG on days 2, 4 and 7; if it falls by 15% or more each time, check weekly until negative; a smaller fall, a rise or new pain needs clinical review
Medical Management Haemodynamically stable; no significant pain; unruptured ectopic mass < 35 mm; no visible heartbeat on TVUS; serum hCG below 1,500 IU/L (methotrexate or surgery offered as a choice at 1,500–4,999 IU/L); no intrauterine pregnancy; normal renal and hepatic function Single-dose intramuscular Methotrexate (50 mg/m²) ; check hCG on days 4 and 7 (hCG must fall > 15% between days 4 and 7); strictly avoid pregnancy for 3 months post-methotrexate
Surgical Management Haemodynamic instability, severe pain, ectopic mass ≥ 35 mm, visible fetal heartbeat, serum hCG ≥ 5000 IU/L, or failure of medical therapy Laparoscopic salpingectomy is first-line; consider laparoscopic salpingotomy if there are risk factors for infertility such as a damaged contralateral tube (hCG at 7 days, then weekly until negative); emergency surgery if in shock. Rhesus-negative women having surgery receive anti-D 250 IU
Caution
Methotrexate Patient Safety: Methotrexate is an antifolate antimetabolite and potent teratogen. Patients must strictly avoid conception for at least 3 months following administration. In addition, patients must avoid folic acid supplements, NSAIDs (which decrease renal clearance of methotrexate), and vigorous sexual intercourse or abdominal examinations that could provoke tubal rupture.
Hyperemesis Gravidarum (HG)
Hyperemesis gravidarum is characterized by intractable, severe nausea and vomiting presenting before 16 weeks gestation, associated with ketonuria, dehydration, electrolyte derangements, and weight loss > 5% of pre-pregnancy weight .
Assessment & Severity Scoring
Evaluated using the validated PUQE (Pregnancy-Unique Quantification of Emesis) score (assessing hours of nausea, episodes of vomiting, and retching).
Typical biochemical profile: Hypokalaemic, hypochloraemic metabolic alkalosis, elevated urea/creatinine (prerenal azotemia), ketonuria (≥ 2+ on dipstick), and secondary mild transaminitis.
Clinical Management Protocol
Intravenous Fluid Resuscitation: Initial rehydration with 0.9% normal saline supplemented with potassium chloride. Potassium must be closely replaced to correct hypokalaemia.
MANDATORY THIAMINE (PABRINEX) RULE: Parenteral thiamine (vitamin B1 / Pabrinex) must be administered BEFORE any dextrose-containing intravenous infusions . Dextrose administration in a carbohydrate-depleted, thiamine-deficient state rapidly exhausts remaining thiamine stores during glycolysis, precipitating acute, irreversible Wernicke's encephalopathy (triad of ataxia, ophthalmoplegia/nystagmus, and acute confusion).
Antiemetic Stepping (RCOG):
First-line: Cyclizine (antihistamine) 50 mg TDS oral/IV/IM, prochlorperazine 5–10 mg TDS, or promethazine.
Second-line: Metoclopramide 10 mg TDS (max 5 days due to extrapyramidal / oculogyric crisis risk) or Ondansetron 4–8 mg BD/TDS.
Third-line: Oral or intravenous corticosteroids (prednisolone or hydrocortisone) in refractory cases.
Thromboprophylaxis: Severe dehydration and pregnancy-induced hypercoagulability produce high venous thromboembolism (VTE) risk. Prescribe prophylactic low molecular weight heparin (LMWH) and anti-embolism stockings during admission.